Insider Transactions in Q2 2025 at Apimeds Pharmaceuticals Us, Inc. (APUS)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Christopher Kim Chairman and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+47.39%
|
-
|
|
May 16
2025
|
Erik C. Emerson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
750,000
+50.0%
|
-
|
|
May 14
2025
|
Christopher Kim Chairman and CMO |
BUY
Open market or private purchase
|
Direct |
7,730
+21.94%
|
$7,730
$1.86 P/Share
|
|
May 13
2025
|
Christopher Kim Chairman and CMO |
BUY
Open market or private purchase
|
Direct |
19,770
+50.0%
|
$19,770
$1.82 P/Share
|
|
May 12
2025
|
Jakap Koo Director |
BUY
Open market or private purchase
|
Direct |
28,500
+4.24%
|
$28,500
$1.99 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
44,041
+2.12%
|
$88,082
$2.6 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
253,092
+2.82%
|
$506,184
$2.6 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
500,000
+20.12%
|
$2,000,000
$4.0 P/Share
|